Full-Time

Bioinformatics Scientist

Pipeline Development

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$120k - $160kAnnually

+ Incentive Compensation + Restricted Stock Units

Junior, Mid

Chicago, IL, USA

Hybrid position requiring in-office presence.

Category
Bioinformatics
Biology & Biotech
Required Skills
Python
Git
BigQuery
SQL
Docker
Google Cloud Platform
Requirements
  • Bachelor's degree in computational biology, bioinformatics, computer science or equivalent, and 2+ years experience in bioinformatics analysis or software engineering
  • An advanced degree in a scientific or computationally related field
  • Computational experience in Python
  • Databases: SQL or BigQuery
  • Software containers, e.g., Docker
Responsibilities
  • Implement ETL/ELT processes for complex, multi-modal molecular, high-throughput screening, and sequencing data in a lab setting
  • Write code to transform data between data models and formats, preferably in Python
  • Use workflow systems (e.g., Nextflow, Snakemake) for pipeline development and automation
  • Build and run resilient data pipelines in development and production through CI/CD best practices
  • Build cloud-native applications and supporting technologies / patterns / practices including: GCP, Docker, GitHub, APIs & microservices
  • Collaborate with subject matter experts, e.g., product, engineering, to design and maintain systems supporting medical devices and clinical pipelines
  • Produce high quality and detailed documentation for all projects

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

15%

2 year growth

36%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.

Help us improve and share your feedback! Did you find this helpful?